News
Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...
Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals’ offer for the DNA-testing company in a bankruptcy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results